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Abstract
The concept of biomedical significance of the functional pairing between tissue lectins and their glycoconjugate counterrecep-
tors has reached the mainstream of research on the flow of biological information. A major challenge now is to identify the 
principles of structure–activity relationships that underlie specificity of recognition and the ensuing post-binding processes. 
Toward this end, we focus on a distinct feature on the side of the lectin, i.e. its architecture to present the carbohydrate rec-
ognition domain (CRD). Working with a multifunctional human lectin, i.e. galectin-3, as model, its CRD is used in protein 
engineering to build variants with different modular assembly. Hereby, it becomes possible to compare activity features of 
the natural design, i.e. CRD attached to an N-terminal tail, with those of homo- and heterodimers and the tail-free protein. 
Thermodynamics of binding disaccharides proved full activity of all proteins at very similar affinity. The following glycan 
array testing revealed maintained preferential contact formation with N-acetyllactosamine oligomers and histo-blood group 
ABH epitopes irrespective of variant design. The study of carbohydrate-inhibitable binding of the test panel disclosed up 
to qualitative cell-type-dependent differences in sections of fixed murine epididymis and especially jejunum. By probing 
topological aspects of binding, the susceptibility to inhibition by a tetravalent glycocluster was markedly different for the 
wild-type vs the homodimeric variant proteins. The results teach the salient lesson that protein design matters: the type 
of CRD presentation can have a profound bearing on whether basically suited oligosaccharides, which for example tested 
positively in an array, will become binding partners in situ. When lectin-glycoconjugate aggregates (lattices) are formed, 
their structural organization will depend on this parameter. Further testing (ga)lectin variants will thus be instrumental (i) to 
define the full range of impact of altering protein assembly and (ii) to explain why certain types of design have been favored 
during the course of evolution, besides opening biomedical perspectives for potential applications of the novel galectin forms.
Keywords Enterocytes · Glycocluster · Glycoprotein · Lectin (engineering) · Thermodynamics
Introduction
What has deterred researchers for decades from working 
with the glycan part of cellular glycoconjugates, i.e. its 
enormous structural complexity [explaining the origin of the 
term ‘complex (hetero)saccharides’ (Ginsburg and Neufeld 
1969; Sharon 1975; Montreuil 1995)], has turned out to be 
the biochemical manifestation of the most versatile means 
to encode biomedically relevant information, and this at an 
exceptionally high density (Winterburn and Phelps 1972; 
Laine 1997; Gabius and Roth 2017; Kaltner et al. 2019). 
Considering the development of the sophisticated enzymol-
ogy for glycan assembly, encompassing 15 distinct pathways 
and at least 169 glycosyltransferases in humans, and of the 
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manifold switches that make generation of a wide diver-
sity of glycan-based signals with highly dynamic regula-
tion (‘(re)writing’) possible (Brockhausen and Schachter 
1997; Reuter and Gabius 1999; Buddecke 2009; Zuber and 
Roth 2009; Hennet and Cabalzar 2015; Schengrund 2015; 
Bhide and Colley 2017; Corfield 2017; Kopitz 2017; Roth 
and Zuber 2017; Ledeen et al. 2018; Narimatsu et al. 2019), 
there is every reason to believe in the validity of the concept 
of the sugar code. Fittingly, the corresponding expectation 
that an equally intricate system evolved during phylogenesis 
for ‘reading’ and ‘interpreting’ sugar-encoded ‘messages’ 
proved entirely true so that sugar-receptor (lectin) interaction 
is being revealed to play the assumed role, that is to underlie 
many (patho)physiological processes (Lis and Sharon 1998; 
Manning et al. 2017a; Kaltner et al. 2018, 2019; Cummings 
2019; Duan and Paulson 2020; Groux-Degroote et al. 2020).
Having realized the fundamental importance of this 
type of functional pairing, it is imperative to understand 
the principles that lead to the context-specific outcomes of 
glycan–lectin binding on the level of cells and tissues. In 
order to gain respective insights, we here focus on a par-
ticular characteristic common for lectins i.e. the typical abil-
ity to reach bi- to oligovalency. As first noted in the case 
of the plant agglutinin concanavalin A, biological activi-
ties, in that case haemagglutination and cap formation on 
murine spleen cells, were disclosed to critically depend on 
the status of subunit aggregation (Gunther et al. 1973). The 
inherent capacity of lectins to cross-link counterreceptors is 
essential to bridge cells. On cell surfaces, it also enables the 
building of lattices of distinct topology that will trigger (or 
not) specific post-binding responses, e.g. to stimulate or to 
block proliferation. On the grounds of this hypothesis, i.e. 
an assumed fundamental relevance of lectin architecture for 
shaping the activity profile of a distinct carbohydrate rec-
ognition domain (CRD), it would make sense to see more 
than a single type of structural assembly occur in a family 
of lectins. Indeed, this is actually the case. With focus on 
the adhesion/growth-regulatory galectins, these multifunc-
tional effectors are separated into three groups in vertebrates 
according to this criterion (Kasai and Hirabayashi 1996; 
Barondes 1997; Hirabayashi 1997, 2018; Cooper 2002; 
Kaltner et al. 2017a; de Jong et al. 2020).
As shown in Fig. 1a, homo- and heterodimers (with-
out/with a linker peptide) and a monomer that is endowed 
with capacity to aggregate are the members of this family. 
Monitoring galectin presence on the network level has dis-
closed an intimately regulated expression for each member 
of the family concerning cell type(s), stage of differentia-
tion and disease status (Toegel et al. 2014; Manning et al. 
2017b, 2018; Nio-Kobayashi 2018; García Caballero et al. 
2020a,b). Since structural aspects of the CRDs of many 
galectins are already well characterized (Iwaki and Hira-
bayashi 2018; Kamitori 2018; Romero and Gabius 2019), 
these endogenous lectins are highly suited for our work 
towards the aim to relate protein design to activity. In addi-
tion to studying the natural galectins, rational engineering 
can be envisioned to broaden the test panel. A question such 
as what will happen if a monomeric galectin becomes homo- 
or heterodimeric could then be answered, and this is possible 
by using the new approach of lectinology 4.0 (Ludwig et al. 
2019a): conceptually, this comparative analysis of natural 
and variant proteins that share the same CRD is a potent 
means to determine design–activity relationships. Due to its 
Fig. 1  Schematic illustration of the three types of modular display of 
vertebrate galectins (a) and of the Gal-3 CRD-based variants tested 
in this study (b). a The first class (i.e. proto-type) is established by 
non-covalently associated homodimers like Gal-1, the second (i.e. 
tandem-repeat type) by linker-connected heterodimers like Gal-8 
and the third (i.e. chimera-type) by Gal-3 (with its combination of 
an N-terminal tail consisting of a sequence with two sites for serine 
phosphorylation (symbolized by a yellow rectangle with two P signs) 
and the following nine non-triple helical collagen-like repeats (pur-
ple rectangles) and the CRD) and its proteolytically truncated form 
termed trGal-3 (or Gal-3 CRD). b The set of variants based on the 
Gal-3 CRD consists of a pair of homodimers and two pairs of het-
erodimers. In each case, two modes of CRD conjugation were used, 
i.e. by directly linking C- and N-termini or by inserting the 33-amino-
acid-long peptide of Gal-8. Concerning the heterodimers, permuta-
tions of the relative positions of the Gal-3 CRD to the Gal-1 CRD 
had been generated (Ludwig et al. 2019b)
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wide spectrum of documented activities in cell biology (for 
reviews, please see Hughes 1994; Newlaczyl and Yu 2011; 
Liu et al. 2012; Funasaka et al. 2014; Nangia-Makker et al. 
2018; Romero and Gabius 2019), we selected the chimera-
type galectin-3 (Gal-3).
Realizing the given concept with the CRD of this galec-
tin, a pair of covalently conjugated (proto-type-like) homodi-
mers and, inspired by the recently documented possibility 
for heterodimer formation involving the Gal-3 CRD and 
proto-type galectins (Miller et al. 2018), the two pairs of 
(tandem-repeat-type-like) heterodimers (with the Gal-1 
CRD) had recently been created (Ludwig et al. 2019b). The 
availability of the probes shown in Fig. 1b, together with 
the two wild-type proteins (i.e. Gal-1 and -3) and proteolyti-
cally truncated (tr)Gal-3 as internal standard, sets the stage 
to reveal whether and how types of modular arrangement of 
the CRD of Gal-3 will affect an experimental read-out. The 
assay platforms used in this study deliberately covered the 
range from binding a ligand that is either free in solution or 
presented on a surface to monitoring interactions with cel-
lular glycomes in sections.
First, isothermal titration calorimetry (ITC) char-
acterized the thermodynamics of disaccharide bind-
ing. In addition to the canonical ligand for galectins, i.e. 
N-acetyllactosamine (LacNAc), we tested the disaccharide 
of the Thomsen–Friedenreich (TF) antigen (CD175), i.e. 
Galβ1,3GalNAc. It is known to exhibit a markedly lower 
affinity for wild-type Gal-1 than for Gal-3 (Sparrow et al. 
1987; Sato and Hughes 1992; Yu et al. 2007; Rapoport et al. 
2008; Tateno et al. 2008; Bian et al. 2011; Krzeminski et al. 
2011; Guha et al. 2013; Rodríguez et al. 2015). Thus, its 
application can further help trace differences between the 
monomeric wild-type Gal-3 and homo- and heterodimers 
with the Gal-3 CRD. Next, (glycan) arrays characterized 
binding profiles to 648 surface-immobilized compounds. In 
order to take the test system to the level of natural glycome 
presentation, we finally performed galectin histochemistry 
on tissue sections, here for two organs known to present 
binding sites for human galectins (Kaltner et al. 2017b; Roy 
et al. 2017; Kutzner et al. 2019). In addition to the common 
specificity control with lactose (Lac) free in solution, two 
bi- or tetravalent glycoclusters were probed to evaluate the 
sensitivity of galectin binding to topological aspects of the 
inhibitor. The results of this study disclosed the possibility 
that cell binding of the Gal-3 CRD and its susceptibility to 
being blocked by a glycocluster can vary with protein archi-
tecture. By using rational modular engineering, this study 
explores so far uncharted territory of activity/specificity 




The wild-type proteins and the six variants shown in Fig. 1b 
were obtained after engineering respective cDNAs and their 
insertion into expression vectors by recombinant produc-
tion in bacteria, purified to homogeneity by affinity chro-
matography on home-made Lac-bearing resin as crucial step 
and labeled under activity-preserving conditions with the 
N-hydroxysuccinimide ester of biotin (Sigma, Munich, Ger-
man), as described (Gabius et al. 1991; Ludwig et al. 2019b), 
for studying binding to arrays and tissue sections.
ITC measurements
Titrations were performed under identical conditions and 
with the same equipment, i.e. a PEAQ-ITC calorimeter 
(Malvern, Westborough, MA, USA), as done previously 
with LacNAc and Gal-1, Gal-3 and five Gal-1-based variants 
(Kutzner et al. 2019). Proteins were prepared for titrations 
either by lyophilization and dissolving freeze-dried material 
or by precipitation with ammonium sulfate, dissolving the 
material and dialyzing the salt-rich solution against buffer 
for equilibration. Processing of the original data was per-
formed within the MicroCal PEAQ-ITC analysis software 
package. A fitted off-set parameter was applied to each titra-
tion to account for background. The one-set-of-sites (each 
CRD with identical binding properties) and sequential bind-
ing models provided in the analysis software were used for 
fitting.
Array measurements
Each microarray on a standard glass microscope slide (Semi-
otik LLC, Moscow, Russia; referred to as a chip) presented a 
panel of 648 compounds (synthetic glycans (> 95% purity), 
glycopeptides from the Horst Kunz laboratory (Institute for 
Organic Chemistry of the Johannes-Gutenberg-University, 
Mainz, Germany), KDO-containing oligosaccharides from 
the Paul Kosma laboratory (University of Natural Resources 
and Life Sciences, Vienna, Austria) and bacterial polysac-
charides from the collection of the Zelinsky Institute of 
Organic Chemistry (Moscow, Russia); detailed informa-
tion on structures and NMR data as well as relevant ref-
erences are available at https ://csdb.glyco scien ce.ru/bacte 
rial; Supplementary Material, Tables S1–S7 list compound 
arrangement on the chips and signal intensity systemati-
cally). When preparing the chip, the glycan concentration 
was routinely set to 50 µM, the polysaccharide concentra-
tion to 10 µg/mL, and that of glycopeptides to 100 µg/mL. 
All ligands were printed at six replicates onto commercial 
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NHS-activated Slide H (Schott Nexterion, Jena, Germany) 
material in a standard procedure (Blixt et al. 2004) by an 
sciFLEXARRAYER S5 non-contact piezo-arrayer with on-
line array quality control (Scienion, Berlin, Germany). The 
drop volume was about 0.9 nL. The glass surface had been 
pretreated with phosphate-buffered saline (20 mM, pH 7.2; 
PBS) containing 0.1% Tween-20 for 15 min to saturate sites 
for protein binding on the glass surface. Probing with a solu-
tion of biotinylated galectins at 50 µg/mL in PBS containing 
0.1% Tween-20, 1% bovine serum albumin (BSA) and 0.01% 
 NaN3 for 1 h at 37 °C in a humidified chamber was followed 
by thorough washing to remove unbound protein and then 
incubation with a solution containing fluorescent streptavi-
din (labeled with the ALEXA-555 dye; Life Technologies, 
Eugene, OR, USA) for 45 min at 20 °C. After washing with 
PBS-0.05% Tween-20 and thereafter with deionized water, 
slides were inserted into a ScanArray Gx scanner (Perki-
nElmer, Shelton, USA) and irradiated with an excitation 
wavelength of 543 nm at 10 μm resolution to measure inten-
sities of signal for bound galectin. The obtained data were 
processed using the ScanArray Express 4.0 software and the 
fixed 70 µm-diameter circle method as well as the Microsoft 
Excel software. Data on the six replicates per compound and 
on all compounds are reported as median relative fluores-
cence units (RFU) and median absolute deviation (MAD). 
A signal, whose fluorescence intensity exceeded the back-
ground by a factor of five, was considered to be significant.
Galectin histochemistry
Specimens of epididymis and jejunum from four six-week-
old C57BL/6 mice were fixed in Bouin’s solution for 24 h, 
dehydrated in a series of solutions containing increasing 
percentage of ethanol [70%, 80% and 99% (v/v)], then in 
isopropanol and in xylene and finally embedded in paraf-
fin. Sections with a thickness of about 5 µm were mounted 
on SuperFrost® Plus glass slides (Menzel, Braunschweig, 
Germany), rehydrated and exposed to blocking solution [1% 
BSA (Sigma-Aldrich, Munich, Germany) in PBS] for 1 h 
at room temperature. Incubation with solutions containing 
biotinylated galectin overnight at 4 °C and signal genera-
tion with Vectastain® ABC Kit and Vector® Red reagents 
(Biozol, Eching, Germany) was performed, as described 
previously when testing wild-type proteins and Gal-1-based 
variants (Kutzner et al. 2019). After counterstaining with 
Mayer’s hemalum, dehydration and mounting in Eukitt® 
(Kindler, Freiburg, Germany), staining profiles were system-
atically recorded with an AxioImager.M1 microscope (Carl 
Zeiss MicroImaging, Göttingen, Germany) equipped with 
an AxioCam MRc3 digital camera, and these data sets were 
processed using the software AxioVision (version 4.9). Sys-
tematic titrations with each galectin and specificity controls 
with the canonical ligand Lac were performed to ensure an 
optimal signal-to-background ratio of carbohydrate-inhibita-
ble binding. In detail, wild-type Gal-3 was tested in the range 
between 0.5 and 16 µg/mL, trGal-3 (Gal-3 CRD) between 
2 and 32 µg/mL and the homo- and heterodimers between 
0.0625 and 2 µg/mL. Cognate sugar (Lac) was added to the 
galectin-containing solution to bind to its receptor and to 
hereby block access to the contact site for glycans, and the 
mixture was then pipetted onto the sections. In addition to 
the free disaccharide, Lac presented by two types of carri-
ers, i.e. a divalent stilbene-based scaffold and a tetravalent 
tetraphenylethylene backbone, prepared as described previ-
ously (Kutzner et al. 2019), served as inhibitor for galectin 
binding in titrations with stepwisely increasing concentra-
tions. The structures of these two glycoclusters are shown 
in Fig. 2. Assessment of staining was independently done 
by two observers. The system for semiquantitative grading 
of intensity of staining is listed in the footnote of Table 4.
Results
The panel of Gal‑3‑based variants
Gal-3 naturally occurs as full-length protein with an N-ter-
minal tail that can be shortened by bacterial and tissue pro-
teases up to complete removal of this section to yield trGal-3 
(Gal-3 CRD) (Hsu et al. 1992; Herrmann et al. 1993; Mehul 
et al. 1994; Ochieng et al. 1994; Gao et al. 2017) (Fig. 1a). 
The loss of collagenous repeats reduces the tendency for 
self-aggregation via the tail and can modulate binding to 
cellular counterreceptors in negative and positive directions 
(Ochieng et al. 1998; Kopitz et al. 2001, 2014). A trun-
cated form of Gal-3 provided crystallographic information 
on interactions between Gal-3 CRDs, a second means to 
enable oligovalency (Flores-Ibarra et al. 2018). This struc-
tural unit was turned into a pair of homodimers by directly 
conjugating C- and N-terminal amino acids of two CRDs or 
by inserting the linker present in Gal-8 between two CRDs 
(Fig. 1b). Hereby, a conversion of the chimera-type Gal-3 to 
a proto-type-like design was achieved, without/with linker 
to probe into importance of this aspect. The same procedure 
generated pairs of tandem-repeat-type-like heterodimers of 
the CRD of Gal-3 with that of Gal-1 (Fig. 1b). With this set 
of eight proteins in hand, properties of the Gal-3 CRD pre-
sented in the two natural forms and as engineered homo- or 
heterodimers could systematically be determined.
Binding properties: ITC
Isothermal calorimetric titrations up to reaching saturation 
of binding sites served two purposes: they first ensure full-
capacity ligand binding (activity) of the proteins, and they 
next provide data sets that define the thermodynamics of 
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ligand binding to the CRD (alone or extended by the tail) 
relative to the different types of the dimers. In order to pre-
clude a major impact of protein processing after purification 
and sample preparation, we worked with lectin preparations 
processed by lyophilization as well as by precipitation with 
ammonium sulfate and dialysis of solution containing the 
dissolved protein for equilibration, if that was possible due to 
solubility. Of utmost importance, this parameter is critical to 
prepare a clear protein-containing solution and to ensure the 
quality of results. Under these conditions, typical titration 
profiles were invariably obtained. Examples for experimental 
data recorded during the titration with LacNAc are presented 
in Fig. 3 (for further illustrations, please see Supplementary 
Material, Fig. S1a–f). In all cases, the calculated n-values 
were close to the theoretical number of the stoichiometry of 
one contact site of cognate sugar per CRD irrespective of the 
type of protein preparation (Table 1). These data ascertain 
the full activity of the test proteins.
Looking at the measured thermodynamics of binding, the 
process is enthalpically driven in all cases (Table 1), as has 
been reported previously for the wild-type Gal-3 proteins 
and also the pair of engineered Gal-3 homodimers (Dam 
Fig. 2  Illustration of the struc-
tures of the two glycoclusters 
(compound 1: bivalent, com-
pound 2: tetravalent) with their 
Lac headgroups in the common 
chair conformer by line draw-
ing and space-filling models 
(please see Kutzner et al. 2019 
for details on synthesis and 
modeling)
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et al. 2005; Ludwig et al. 2019b). When performed under 
identical conditions in the same study, affinity for this ligand 
had been found to be very similar for Gal-1 and -3 (Ahmad 
et al. 2002; Dam et al. 2005). Quality of protein preparations 
was hereby ensured, as it was justified to apply the one-
set-of-sites model for data fitting. The homodimerization 
of this CRD did not affect results markedly (Table 1). The 
calculated data for the two pairs of heterodimers matched 
this pattern irrespective of the order of the two types of CRD 
from N- to C-terminus or the type of conjugation (with-
out/with linker) (Table 1). Data fitting using the (Malvern) 
sequential model led to an indication for this type of an 
Fig. 3  ITC titration profile of LacNAc (6.0  mM) binding to a 
Gal-3–Gal-3 (55  μM), b Gal-3–8S–Gal-3 (61  μM), c Gal-3–Gal-1 
(46  μM), and d Gal-3–8S–Gal-1 (24  μM) in phosphate-buffered 
saline (pH 7.2) containing 20  mM phosphate, 10  mM NaCl and 
2 mM β-mercaptoethanol. Lectins are prepared by lyophilization (b, 
d) or precipitation by ammonium sulfate (a, c). Injections of ligand 
were performed every 150 s at 298 K. The top panels show the ther-
mogram and bottom panels the isotherm for data processing using 
MicroCal PEAQ-ITC analysis software. Resulting values for the 
stoichiometry (n), binding affinity (Ka), dissociation constant (Kd), 
enthalpy (ΔH), and the TΔS term are given in Table 1
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alternative process cascade in the case of the heterodimer 
Gal-3–8S–Gal-1 with Kd-values of 62.3 ± 0.003 µM/394.
0 ± 86.9 µM, implying a possibility for negative coopera-
tivity in this case. Of relevance, the Scatchard analysis of 
galectin binding to the surface of human neuroblastoma 
cells had revealed no deviation from linearity for the four 
heterodimers with Gal-1/-3 CRDs (Ludwig et al. 2019b), 
in essence favoring an operative single-set-of-sites binding 
in this context.
When test ing the second disacchar ide,  i .e . 
Galβ1,3GalNAc, the affinity for Gal-1 expectably turned out 
to be very low. Control titrations with the pair of covalently 
linked Gal-1 homodimers failed to provide signals on heat 
release for reliable affinity calculations. In a recent report, 
a difference of 47 µM (Gal-3) to 4 mM (Gal-1) had been 
reported by ITC with this disaccharide (Bian et al. 2011). As 
done for the series of titrations with LacNAc, respective pro-
files for wild-type and variant proteins with the Gal-3 CRD 
are presented exemplarily in Fig. 4 (for further illustrations, 
please see Supplementary Material, Fig. S2a–d). Fitting the 
data sets for the Gal-3 homodimers appeared to result in a 
similar affinity as measured for the wild-type forms mono-
meric in solution (Table 2). Considering the profoundly dif-
ferent affinity of this disaccharide to the Gal-1 and Gal-3 
CRDs, the sequential model was applied for data obtained 
with the heterodimers. It derived estimates for the affinity of 
the Gal-1 CRD for this disaccharide in heterodimers in the 
up to high mM range at full loading (Table 3). Intuitively, 
given the wide disparity in affinity between Gal-3 and -1 
CRDs for this disaccharide, applying a two-sets-of-sites 
model appears appropriate, and the hereby calculated data 
by and large reflect the properties of the individual domains, 
with the exception of an entropically favored second bind-
ing step in the case of the Gal-3–8S–Gal-1 heterodimer 
(Table 3).
Overall, a monovalent ligand in solution can access the 
contact sites in Gal-3 CRD-based homo- and heterodimers. 
Binding of the two tested ligands to homodimers appears 
to fit a model well without involving cooperativity. Like 
homodimers, heterodimers can also be fully saturated with 
suited ligand. The affinity data appear to reflect the respec-
tive levels of binding activity of each type of CRD. Analysis 
of interactions is next taken to the level of increased diver-
sity by testing an array with these proteins under identical 
conditions.
Binding properties: glycan arrays
In this test system, the wild-type proteins and the six bivalent 
variants can associate to a surface-exposed compound by a 
single contact and, more firmly, by cross-linking two sites 
of the same type of ligand presented on the chip surface. Of 
note, each spot presents a single type of compound. That 
non-uniform results in qualitative and quantitative aspects 
were obtained among the set of 648 compounds excluded 
non-specific binding, that β-galactoside-containing glycans 
were preferred binding partners fulfilled the expectation that 
is based on the maintained lectin activity in all proteins, as 
ascertained by the ITC titrations. The side-by-side compari-
son of signal intensity for the top-20 glycans is presented 
in Fig. 5. Obviously, binding depends on the nature of the 
printed substance (please see Supplementary Material, Fig. 
S3 for a bar graph; for complete listings of signal intensity 
for each array and protein, please see Supplementary Mate-
rial, Tables S1–S7).
Main binding partners of the Gal-3 CRD in the natural 
chimera-type constellation and in homo- and heterodimers 
are LacNAc oligomers, histo-blood group ABH epitopes 
and the xenoantigen with the α1,3-Gal extension to the 
LacNAc core (Fig. 5). When faced with structurally homo-
geneous surface presentation of glycans in an array, this 
set of variant proteins was active and has a rather similar 
profile for the high-intensity-signal cases, corroborating 
the ITC-based results on activity. As the data of the full-
scale analysis given in the Supplementary Material, Tables 
S1–S7 disclosed, some differences appeared that depend on 
Table 1  Summary of thermodynamics of binding of LacNAc (6.0 mM) to galectins at 25 °C calculated using the one-set-of-sites binding model
a/b Data obtained with lyophilized  proteina or with protein precipitated, then dissolved and  dialyzedb
c From Kutzner et al. 2019
[Cell] (μM) n Ka (× 104 M−1) − ΔG (kcal/mol) − ΔH (kcal/mol) − TΔS (kcal/mol) Kd (μM)
Gal-3a 118 1.11 2.67 6.04 12.7 ± 0.07 6.65 37.5 ± 0.48
Gal-3  CRDa 90 0.97 2.19 5.92 9.70 ± 0.27 3.78 45.6 ± 1.64
Gal-3–Gal-3b 55 2.00 2.76 6.06 15.0 ± 0.17 8.90 36.2 ± 0.78
Gal-3–8S–Gal-3a 61 1.96 3.40 6.18 11.2 ± 0.14 5.03 29.4 ± 0.92
Gal-1–Gal-3b 67 1.98 1.69 5.77 13.4 ± 0.19 7.59 59.0 ± 1.45
Gal-1–8S–Gal-3a/b 55/50 1.93/1.83 2.08/1.86 5.90/5.82 11.9 ± 0.27/12.9 ± 0.22 5.99/7.03 48.0 ± 1.71/53.9 ± 1.32
Gal-3–Gal-1b 46 2.01 2.01 5.87 15.2 ± 0.22 9.36 49.7 ± 0.95
Gal-3–8S–Gal-1a/b 24/28 1.96/1.96 1.67/1.59 5.77/5.74 14.3 ± 0.46/ 11.9 ± 1.10 8.52/6.52 60.0 ± 1.10/63.0 ± 3.83
Gal-1a,c 110 2.09 1.17 5.55 9.81 ± 0.08 4.26 85.2 ± 1.52
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the modular organization in this setting of ligand presenta-
tion. In order to answer the question what will happen when 
the surface presents diverse types of glycans, i.e. the natural 
glycome, with possibilities to form bridges between non-
identical glycans, we proceeded to analyze galectin binding 
to tissue sections.
Fig. 4  ITC titration profile of Galβ1,3GalNAc (6.0  mM) binding 
to a Gal-3–Gal-3 (55  μM), b Gal-3–8S–Gal-3 (90  μM), c Gal-3–
Gal-1 (30  μM), and d Gal-3–8S–Gal-1 (52  μM) in phosphate–buff-
ered saline (pH 7.2) containing 20  mM phosphate, 10  mM NaCl 
and 2  mM β-mercaptoethanol. Lectins are prepared by lyophiliza-
tion (b) or precipitation by ammonium sulfate (a, c, d). Injections of 
ligand were performed every 150  s at 298  K. The top panels show 
the thermogram and bottom panels the isotherm for data process-
ing using MicroCal PEAQ-ITC analysis software. Resulting values 
for the stoichiometry (n), binding affinity (Ka), dissociation constant 
(Kd), enthalpy (ΔH), and the TΔS term are given in Table 2 for the 
homodimers and in Table 3 for the heterodimers
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Table 2  Summary of thermodynamics of binding of Galβ1,3GalNAc (6.0 mM) to Gal-3 mono- and homodimers at 25 °C calculated using the 
one-set-of-sites binding model
a/b Data obtained with lyophilized  proteina or with protein precipitated, then dissolved and  dialyzedb
[Cell] (μM) n Ka (× 104 M−1) − ΔG (kcal/mol) − ΔH (kcal/mol) − TΔS (kcal/mol) Kd (μM)
Gal-3a 110 1.02 0.45 4.99 9.95 ± 1.37 4.99 222 ± 18.5
Gal-3  CRDa 90 0.95 0.38 4.88 7.64 ± 0.95 2.75 264 ± 13.7
Gal-3–Gal-3b 55 1.97 0.34 4.83 14.9 ± 0.31 10.1 288 ± 3.01
Gal-3–8S–Gal-3a 90 1.95 0.64 5.19 6.92 ± 0.18 1.73 157 ± 4.69
Table 3  Summary of thermodynamics of binding of Galβ1,3GalNAc (6.0 mM) to the four heterodimers at 25 °C calculated using the sequential 
binding model







− ΔH1/− ΔH2 (kcal/mol) − TΔS1/− TΔS2 
(kcal/mol)
Kd1/Kd2 (μM)
Gal-1–Gal-3a 53 2.00 1.25/1.75 5.60/4.40 5.82 ± 0.07/11.0 ± 0.41 0.22/6.60 80 ± 0.024/569 ± 0.167
Gal-3–Gal-1a 30 2.00 0.81/2.03 5.31/4.55 10.8 ± 0.19/12.7 ± 0.87 5.49/8.15 122 ± 3.58/491 ± 14.5
Gal-1–8S–Gal-3a 45 2.00 0.61/0.06 12.12/5.5 8.87 ± 0.311/5.05 ± 3.01 3.70/1.20 162 ± 0.006/1520 ± 652
Gal-3–8S–Gal-1a 52 2.00 0.44/0.12 4.98/4.21 3.06 ± 0.230/− 6.89 ± 0.423 − 1.92/− 11.1 225 ± 26.7/774 ± 92
Fig. 5  Stacked chart of signal intensities of binding of eight proteins to top-level glycans in the 648-compound-based array (each colored part of 
the bar is the relative signal intensity (in relative units) for the given pair of protein and glycan)
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Binding properties: tissue sections
The advantage of this test system for our comparative study 
is the simultaneous monitoring of galectin binding to vari-
ous cell types in a section so that the likelihood of missing 
differences in staining properties between cell populations is 
reduced. Toward this end, we performed the histochemical 
analyses on two organs from the reproductive and the diges-
tive systems, i.e. murine epididymis and jejunum.
Following systematic titrations to determine experimental 
conditions that lead to optimal signal-to-background read-
ings, the individual profiles of carbohydrate-inhibitable 
binding were assessed under identical technical conditions 
(processing of sections, generation of signal and its semi-
quantitative assessment). As exemplarily documented in 
the inset of Fig. 6a, cognate sugar (Lac) abolished staining 
(please see also below for inhibition by Lac-containing gly-
coclusters; data on binding of full-length Gal-3 to sections 
of murine epididymis and/or jejunum had previously been 
published by Kaltner et al. (2017b), Roy et al. (2017) and 
Kutzner et al. (2019). In this study, the two wild-type Gal-3 
proteins (full-length and proteolytically truncated Gal-3) 
were compared first on sections of fixed specimens of adult 
murine epididymis. Incubation of sections with full-length 
Gal-3 and the product of proteolytic truncation (Gal-3 CRD) 
led to similar distribution of staining with positivity in api-
cal, basal and principal cells (Fig. 6a, b; Table 4). When 
presented as homodimer, a cell type-dependent change was 
detected. Serving as internal control for activity, cytoplasm 
of basal cells remained strongly stained, whereas principal 
and apical cells lacked signals (Fig. 6c, d). The type of cova-
lent CRD connection for homodimerization in this case obvi-
ously made no difference. If one Gal-3 CRD is substituted by 
a Gal-1 CRD, principal and apical cells were stained by the 
respective sets of heterodimers (Fig. 6e–h). Expectably, Gal-
1, when used as internal control, bound principal, apical and 
basal cells (Fig. 6i; please see also Kutzner et al. 2019). In 
the case of principal and apical cells, the protein architecture 
and the composition of the dimers had a bearing on associa-
tion with the Gal-3 CRD, as summarized in Table 4. In order 
to figure out whether variability based on the cell type can 
occur also in other cell types, we monitored galectin binding 
in a second type of organ, i.e. murine jejunum.
In this case, detailed analysis of staining profiles obtained 
with full-length Gal-3 and the Gal-3 CRD revealed, besides 
similarities, notable differences for goblet cells (Table 5). 
This aspect is highlighted by inserts to Fig. S4a, b presented 
in the Supplementary Material. The contents of goblet cells 
were especially prone to serve as ligand for the Gal-3 CRD; 
when the lectin domain is a part of homo- or heterodimers, 
no staining appeared (Table 5). Interestingly, enterocyte 
staining could be discriminatory in the case of the two 
homodimers (Supplementary Material, Fig. S4c, d), while 
cells at the crypts’ base were uniformly stained and pat-
terns of immune cell positivity were also very similar (Sup-
plementary Material, Fig. S4a–h). The internal standard of 
Gal-1-dependent positivity appeared to have quantitative dif-
ferences to profiles obtained with heterodimers, especially 
evident for enterocyte staining (Supplementary Material, 
Fig. S4e–i; Table 5). Designed to highlight differences at a 
glance, Fig. 7 representatively compares staining profiles of 
surface enterocytes of villi (Fig. 7a) and of the base of crypts 
(Fig. 7b) for full-length Gal-3, the Gal-3–Gal-3 homodimer 
and the Gal-3–Gal-1 heterodimer. The exceptionally strong 
staining intensity of the supranuclear region of the entero-
cytes by the homodimer (Fig. 7a) in contrast to the strong 
(+ + +) to very strong (+ +  + +) level of staining of crypt 
cells (Fig. 7b) depicts a prominent case of difference.
In addition to probing the characteristics of Lac-inhibita-
ble cellular staining in sections, topological aspects of bind-
ing were examined. To do so, two glycoclusters with bi- or 
tetravalency were applied for systematic inhibition studies 
(Fig. 2). As documented in detail previously in Kutzner et al. 
(2019), the distances between sugar headgroups are up to 
33 Å in the bivalent compound 1 and 18 Å, 28.5 Å and 32 Å 
for compound 2, what is also shown in Fig. 2. The exem-
plary illustration in Fig. 8 documents the effect of valency 
on staining intensity in epididymis for the Gal-3–Gal-3 
homodimer (a–d) and the Gal-1–Gal-3 heterodimer (e–h). 
At 0.01 mM Lac in all cases, control values were obtained 
(Fig. 8a, e for free Lac, Fig. 8c, g for compound 1 and insets 
Fig. 6  Illustration of staining profiles by wild-type Gal-3 (and Gal-
1), the Gal-3 CRD (trGal-3) and engineered homo- and heterodimers 
of Gal-3 (and Gal-1) in cross sections through the initial segment of 
fixed murine epididymis. a Signal intensity for Gal-3 binding was 
weak in the cytoplasm of principal cells (arrows) and moderate in 
apical (white arrowheads) cells and, supranuclearly, in principal cells. 
Cytoplasm of basal cells (black arrowheads) was strongly positive. 
Inset to a shows extent of reduction of binding by co-incubation of 
biotinylated Gal-3 with the cognate sugar Lac (200 mM). b Moder-
ate staining in the cytoplasm of principal (arrows) and apical (white 
arrowheads) cells, strong cytoplasmic positivity in basal cells (black 
arrowheads) by trGal-3. c, d Engineered Gal-3 homodimers (Gal-3–
Gal-3, c; Gal-3–8S–Gal-3, d) stained the cytoplasm of basal cells 
particularly strong (black arrowheads), whereas principal (arrows) 
and apical (white arrowheads) cells appeared to be negative. e–h 
Binding of the four heterodimers (Gal-3–Gal-1, e; Gal-3–8S–Gal-1, f; 
Gal-1–Gal-3, g; Gal-1–8S–Gal-3, h) resulted in medium level stain-
ing intensity in the cytoplasm of principal (arrows) and apical (white 
arrowheads) cells. In the cytoplasm of basal (black arrowheads) cells, 
strong positivity with the two heterodimer variants Gal-3–Gal-1 (e) 
and Gal-3–8S–Gal-1 (f) and very strong positivity for the two vari-
ants Gal-1–Gal-3 (g) and Gal-1–8S–Gal-3 (h) was recorded. i Pro-
cessing with labelled Gal-1 led to moderate and uniform cytoplasmic 
staining in the epithelial lining (principal cells, arrows; apical cells, 
white arrowheads; basal cells, black arrowheads). The following 
concentrations were applied: Gal-3: 2.0  µg/mL; trGal-3: 16.0  µg/
mL; Gal-3–Gal-3, Gal-3–8S–Gal-3, Gal-3–Gal-1, Gal-3–8S–Gal-1, 
Gal-1–Gal-3, Gal-1–8S–Gal-3, Gal-1: 0.0625 µg/mL. Scale bars are 
20 µm
◂
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to Fig. 8a, e for compound 2). This is also symbolized by 
adding the category of semiquantitative intensity assessment 
to the figures. The increase of Lac concentration to 0.1 mM 
did not affect galectin binding for free sugar (Fig. 8b, f) 
and sugar presented by the tetravalent compound (insets to 
Fig. 8b, f). The bivalent presentation increased inhibitory 
potency, thus reducing signal intensity, also decreasing the 
number of positive basal cells (Fig. 8d, h). This compound 
was also preferentially active on binding of full-length Gal-3 
and of Gal-1, especially potent as inhibitor of binding of the 
Gal-3 CRD (not shown). The same tendency prevailed in the 
respective testing on sections of murine jejunum, illustrated 
as done above for epididymis (Supplementary Material, Fig. 
S5). However, in these sections, tetravalency proved equally 
inhibitory to bivalency for full-length Gal-3 but less so and 
heterogeneously in effect for the dimeric Gal-3 CRD-based 
variants or weakly for Gal-1 (Fig. 9).
Discussion
Protein (lectin)–glycan interactions govern a broad range of 
important activities in physiology and pathogenesis. To do 
so, several structural factors on both sides of the functional 
pairing likely team up to establish diversity (on the level of 
a cell type and between different cell populations) and speci-
ficity (Gabius et al. 2011, 2016), and this hypothesis drives 
research to define the relative extents of their contributions. 
Suggesting a conspicuous relevance, lectin structure in 
Nature is not restricted to the simple occurrence as a CRD. 
Instead, it comes in different forms, as shown for vertebrate 
galectins in Fig. 1a. This obvious selection from a broader 
range of possibilities during phylogenesis prompts to ask 
questions on the functional meaning of the various types of 
design. Guided by the intention to trace clues to explain the 
natural preferences, protein engineering makes the compari-
son of the activity of a CRD in different structural contexts 
(natural or artificial) possible.
Using human Gal-3 as a model, we have addressed this 
complex issue experimentally in three assay systems by 
studying the (full-length) wild-type protein and its CRD, 
a natural switch of structure by proteolysis in situ, and a 
panel of six homo- and heterodimeric variants. As noted 
before (Dam et al. 2005), the presence of the N-terminal 
tail will not markedly affect the thermodynamics of disac-
charide binding, a property referred to as “individuality of 
the domains” by Agrwal et al. 1993. Free disaccharides and 
a wide array of glycocompounds (displayed homogeneously 
on a chip) interact with this CRD in all tested proteins rather 
uniformly, that is mostly irrespective of protein design. The 
reported preference to LacNAc oligomers, histo-blood group 
ABH epitopes and the α1,3-Gal-based xenoantigen is in full 
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Fig. 7  At-a-glance illustration of differences in staining patterns 
of biotinylated Gal-3, its engineered homodimer Gal-3–Gal-3 and 
the Gal-3–Gal-1 heterodimer in enterocytes of villi (a) and the base 
of crypts (b) in sections of fixed murine jejunum. a Weak supranu-
clear staining in the cytoplasm of enterocytes by Gal-3 in contrast to 
the strong supranuclear positivity (arrowhead) for the Gal-3–Gal-3 
homodimer. The staining profile for the Gal-3–Gal-1 heterodimer was 
characterized by a diffuse positivity of moderate intensity in the api-
cal part of the cytoplasm. The brush border (bb) was weakly positive 
in the cases of Gal-3 and Gal-3–Gal-1 but moderately positive for the 
Gal-3–Gal-3 homodimer. Immune cells at the lamina propria (aster-
isk) were strongly stained by all lectins and contents of goblet cells 
(arrows) was invariably negative. b Strong cytoplasmic positivity in 
crypt cells (arrows) was observed for Gal-3, signal intensity increased 
to very strong for the homo- and heterodimers. Enterocytes (white 
arrowheads) were negative in all three cases, contents of goblet cell 
precursors (black arrowheads) was stained exclusively by the homodi-
mer. The concentration of labeled lectin was 4 µg/mL (for Gal-3) or 
0.0625 µg/mL (for both variants). Scale bars are 10 µm
Fig. 8  Illustration of effect of increasing concentrations of cognate sugar (Lac) 
either used as free disaccharide or as ligand part of two synthetic glycoclus-
ters on the staining profile obtained with biotinylated Gal-3–Gal-3 (a–d) or 
Gal-1–Gal-3 (e–h) in cross sections through the initial segment of fixed murine 
epididymis. When applying 0.01 mM Lac as free sugar (a, e) or as part of a 
neoglycoconjugate, i.e. the bivalent compound 1 (c, g) or the tetravalent com-
pound 2 (insets to a and e), signal distribution and intensity were not affected. 
Increasing the sugar concentration to 0.1 mM (b, f; free Lac; insets to b and f; 
compound 2) did not lead to a significant reduction in staining intensity (for 
positive control at 200 mM, please see Fig. 6 inset to a). In contrast, presence 
of 0.1 mM Lac as ligand part of compound 1 decreased the staining intensity 
by one (from +  +  +  + to +  +  +; d) to three (from +  +  +  + to + (principal 
cells)/+  + (basal cells); h) categories in the semiquantitative ranking; the 
number of positive basal cells was reduced to approximately 20% (d) or 60% 
(h). Semiquantitative grading of staining intensity is classified according to a 
footnote in Table  4, respective symbols are presented in the rectangle in the 
top-right part of each photomicrograph and inset. Scale bars are 20 µm. Gal-3–
Gal-3 was applied at 0.25 µg/mL, Gal-1–Gal-3 at 0.125 µg/mL
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binding assays, also arrays (Sparrow et al. 1987; Sato and 
Hughes 1992; Knibbs et al. 1993; Feizi et al. 1994; Jin et al. 
2006; Stowell et al. 2008; Iwaki and Hirabayashi 2018). A 
similar conclusion had been reached by ITC and array analy-
ses of Gal-1 CRD-based homodi- and tetramers (Kutzner 
et al. 2019). Corroborating this evidence, inserting a rigid 
α-helix-forming linker (34 amino acids, thus similar in 
length to the Gal-8S linker, from bacterial ribosomal L9 pro-
tein) into a Gal-1 homodimer maintained the typical binding 
activity toward extended core 2 O-glycan and to the biant-
ennary N-glycan with terminal LacNAc (Earl et al. 2011).
In contrast, the parameter of protein architecture yet mat-
tered, when processing tissue sections with their structur-
ally heterogeneous distribution of binding sites (in terms 
of glycan sequences and topology of presentation). Besides 
similarities, aspects of non-uniform (cell-type-dependent) 
staining in the profiles were detected, and this was also the 
case for homo- vs heterodimer. Moreover, design of a glyco-
cluster applied as inhibitor, here tetravalency on a tetraphe-
nylethylene core, could affect signal intensity differentially 
in relation to the design of the labeled lectin. This obser-
vation points to topological disparities among the cross-
linked aggregates, on cell surfaces called lattices. Explicitly, 
it appears to make a difference for the extent of inhibition 
on certain cell types and different regions in the sections, 
whether the Gal-3 CRD is tested alone, as natural full-length 
conjugate together with its tail or as homodimer. Since the 
level of organization of cross-linked complexes with free 
glycans (e.g. pentasaccharides) or glycoproteins had been 
found to be different between Gal-3 (“disorganized cross-
linked lattice”) and Gal-1 (“(homogeneously) organized” 
instead) (Ahmad et al. 2004) and homodimerization of the 
Gal-3 CRD has been shown to convert wild-type Gal-3 from 
an antagonist of growth-regulatory Gal-1 to an equally effec-
tive signal inducer (Ludwig et al. 2019b), the architecture of 
CRD presentation for counterreceptor binding and aggregate 
organization on cells is most likely fundamentally signifi-
cant. Nature of cell type or tissue constituent can certainly 
come into play for the experimental outcome, extrapolating 
from our data on histochemical staining presented above. 
They therefore underscore the enormous potential of the 
strategy of using a CRD as building block for more than 
one type of lectin design, along with generating glycome 
diversity.
In combination, the reported profiles of staining and gly-
cocluster inhibition when systematically testing the eight 
proteins with the Gal-3 CRD as common unit give direction 
to proceed to investigate the architecture-activity relation-
ship in functional assays. Looking at our data on cell-type-
dependent differences of staining in sections, an extrapola-
tion of functional data for variants obtained in a special cell 
system, for example for heterodimers and neuroblastoma 
cells (Ludwig et al. 2019b) or for Gal-1/-3 heterotetramers 
and T leukemic cells (Fettis et al. 2019), to any other system 
appears to be precluded.
Fig. 9  At-a-glance illustration of differences of the inhibitory effect 
of tetravalent compound 2 (tested at 0.5  mM Lac) on binding of 
biotinylated Gal-3, its engineered homodimer Gal-3–Gal-3 and Gal-l 
to sections of fixed murine jejunum in two panels (a, b). Signal for 
binding of Gal-3 was strongly reduced in cells of the villi includ-
ing enterocytes (arrowhead), their brush border (bb), goblet cells 
(arrow) and the lamina propria (asterisk) (a) and also (b) in cells 
at the crypts’ base (arrow), in enterocytes (black arrowhead) and in 
goblet cell precursors (white arrowhead). In contrast, extent of bind-
ing of the Gal-3–Gal-3 homodimer was less potently reduced in the 
supranuclear region of villi enterocytes (arrowhead, a) and no inhibi-
tion was seen in the cells at the crypts´ base (b). Exposure to tetrava-
lent compound 2 had no effect on Gal-1 binding to the villi or crypt 
regions (a, b). Concentrations used were: Gal-3, 4  µg/mL; Gal-3–
Gal-3, 0.25 µg/mL and Gal-1, 0.5 µg/mL. Scale bars are 10 µm
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As a perspective, the availability of such variants, on the 
level of the cDNA and the protein, will facilitate a series of 
lines of functionally oriented research, starting with inter-
rogating Gal-3 CRD-sharing proteins for consequences con-
cerning the routes of galectin export from cells. After all, 
all galectins lack a signal sequence so that they first func-
tion intracellularly and then leave the cell by a variety of 
pathways (Hughes 1999; Sato 2018; Kutzner et al. 2020). 
Considering the multifunctionality that galectins have intra- 
and extracellularly, and this with specificity for the cell type 
(and its special status of activation of differentiation) (Kasai 
1997, 2018; García Caballero et al. 2020a), work on more 
than a few assay systems will have to be done to characterize 
the role of this aspect of galectin structure reliably. Concern-
ing the interplay with glycan counterreceptors, bottom-up 
tailoring of test platforms such as membrane-surface-like 
monolayers or nanoparticles such as glycodendrimersomes 
has already proven informative (Percec et al. 2013; Majew-
ski et al. 2015; Gabius 2017; Xiao et al. 2018).
Equally important, the variants have the potential to 
become tools for innovative applications. Drawing an anal-
ogy to suggestions for explaining the occurrence of galectin 
tetramers in oysters (Tasumi and Vasta 2007; Feng et al. 
2015; Kopitz et al. 2017) and drawing on Gal-3’s capac-
ity as receptor for pathogen-associated molecular patterns 
(Sato et al. 2009), potent agglutination of bacteria (or neu-
tralization of lipopolysaccharides) could be achieved by 
Gal-3-based oligomers. With respect to galectin-triggered 
signaling, its outcome could be given a desired direction by 
applying the CRD in the best-suited-for-success design. For 
example, the growth-regulatory activity of wild-type Gal-1 
had been either enhanced (by tetramerization) or impaired 
(by conversion to a Gal-3-like design), the precedent for 
galectin design acting as molecular on/off switch (Kopitz 
et al. 2017; Ludwig et al. 2019b). Inspired by these insights 
into structure–activity relationships, the choice of the CRD 
can well be extended to other types of human lectins so that 
siglec or selectin CRDs are envisioned as building block for 
redesigning lectins and even creating puzzle-like combina-
tions. In addition to taking further steps in our concept by 
functional analysis, they can become valuable additions to 
the toolbox for cyto- and histochemical glycophenotyping 
by lectins, currently stocked with natural plant, invertebrate 
and fungal proteins (Roth 1987, 2011).
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